Biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets. Sequence Bio makes use of Newfoundland and Labrador’s founder population and unique history as a cohort to explore to disease preventions and treatments. This population has a high rate of complex and inherited diseases which provides an opportunity to find underlying differences that affect disease and health. Findings are expected to improve the lives of people in Newfoundland and Labrador (NL) and around the world. One of the goals is the share research findings and integrate precision into their local healthcare system.
CEO Chris Gardner was appointed to the federal Health/Bio-sciences Economic Strategy Table by the Minister of Innovation, Science and Economic Development. CSO Michael S. Phillips previously held roles at Genomics Medicine Ireland and Merck. The company won the Community Impact and Business Excellence awards at the St. John’s Board of Trade Awards. Sequence Bio worked with Senator Jim Cowan to support passage of Bill S201 that ensures all Canadians are protected from genetic discrimination.
Sequence Bio is leading the NL Genome Project, a large-scale genomics research study that uses saliva samples for researching DNA combined with medical information in 2500 volunteers. Volunteers are enrolled at select doctor’s offices in the province.
Sequence Bio launches N.L. Genome Project
July 24, 2019